DashboardAll companies
Run this on your own research
Healthcare · Biotechnology

Incyte Corporation

INCYNASDAQ$115.71−$1.22 (−1.04%)Market closed

Price Chart

Daily

Key facts

Market Cap
$23.19B
P/E
17.6x
P/B
4.37x
ROE
29.9%

Incyte Corporation

Healthcare · Biotechnology · FY 2025

Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.

CEO
Mr. Herve Hoppenot
Employees
2,617
Website
incyte.com

Company Statistics

Valuation

P/E
17.6x
P/B
4.37x
P/S
4.39x
EV/EBITDA
12.5x
P/FCF
17.0x

Margins

Gross
92.8%
EBITDA
30.5%
Operating
26.1%
Pre-Tax
32.4%
Net
25.0%

Returns

ROA
20.7%
ROE
29.9%
ROIC
26.9%

Growth (CAGR)

Rev 3Yr
14.8%
Rev 5Yr
14.0%
Op Inc 3Yr
31.4%
Net Inc 3Yr
55.7%

Financial Health

Cash & Cash Equivalents
$3.10B
Net Debt
−$1.31B
Debt/Equity
34.6%
Interest Cov
—

Profile

Revenue
$5.14B
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Incyte Corporation (INCY) Stock Forecast 2026 $115.71 — Price, Financials & Analyst Targets | AlphaLenz